| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/03/2004 | US20040106896 System and method for forming a non-ablative cardiac conduction block |
| 06/03/2004 | US20040106825 e.g., disodium N-(5-chlorosalicyloyl)-8-amN-(10-[2-hydroxybenzoyl]amino)decanoate and disodium N-(10-[2-hydroxybenzoyl]amino)decanoate |
| 06/03/2004 | US20040106778 Interferon gamma-like protein |
| 06/03/2004 | US20040106775 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/03/2004 | US20040106774 Producing uniform distribution of beads with uniform bead to bead performance characteristics for use in solid phase synthesis of polypetide therapeutics |
| 06/03/2004 | US20040106772 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 06/03/2004 | US20040106763 Linear block polymer |
| 06/03/2004 | US20040106730 Polymer complexes of glucuronoglucanes |
| 06/03/2004 | US20040106668 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin |
| 06/03/2004 | US20040106598 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 06/03/2004 | US20040106583 Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity |
| 06/03/2004 | US20040106571 modulator of tumor growth and metastasis in certain cancer types, especially breast and lung cancer |
| 06/03/2004 | US20040106570 down-regulate the expression of the RI alpha gene while producing fewer side effects than conventional oligonucleotides. In particular demonstrate reduced mitogenicity, reduced activation of complement and reduced antithrombotic properties |
| 06/03/2004 | US20040106569 as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target |
| 06/03/2004 | US20040106565 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 06/03/2004 | US20040106564 Use of slpi for treating chronic inflammatory intestinal diseases |
| 06/03/2004 | US20040106561 comprises phytoestrogen isolated from red clover or soya, selected from genistein, daidzein, biochanin A, and/or formononetin; for treatment/prevention of cancer |
| 06/03/2004 | US20040106560 such as N1-L-Arginylspermidine for protecting from damage from extended ischemic/hypoxic events |
| 06/03/2004 | US20040106559 for inhibiting proteases |
| 06/03/2004 | US20040106558 Hydroxamate-containing cysteine and serine protease inhibitors |
| 06/03/2004 | US20040106557 Peptide ligands for prostate specific antigen |
| 06/03/2004 | US20040106556 solvent extraction; amyloid precursor proteins |
| 06/03/2004 | US20040106554 polypeptide analogs of myelin basic protein for treatment of multiple sclerosis |
| 06/03/2004 | US20040106553 Methods for preventing and treating microbial infections by modulating transcription factors |
| 06/03/2004 | US20040106552 amyloid precursor proteins; for use in treatment of Alzheimer's disease/neurodegenerative diseases and as cognitive enhancers |
| 06/03/2004 | US20040106550 comprises chondromodulin-1 protein which grows articular chondrocytes by itself or under coexistence with fibroblast growth factor, and is capable of suppressing hyper degradation of cartilage matrix; gene therapy |
| 06/03/2004 | US20040106549 Anti-angiogenic proteins and methods of use thereof |
| 06/03/2004 | US20040106548 amide cyclization; for altering stability and specificity of receptor-targeted agents |
| 06/03/2004 | US20040106547 glucose lowering protein (GLP-1); exendins; for regulation of excess levels of blood glucose and/or regulation of gastric emptying; for treatment of diabetes and eating disorders |
| 06/03/2004 | US20040106546 comprises cyclosporin, hyaluronic acid, and polysorbate compound |
| 06/03/2004 | US20040106545 Compounds and methods for modulating cell adhesion |
| 06/03/2004 | US20040106544 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements |
| 06/03/2004 | US20040106543 Treatment of diabetes with rosiglitazone and insulin |
| 06/03/2004 | US20040106542 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 06/03/2004 | US20040106541 Protein complex from ion-exchange chromatography for treatment of bacterial infections |
| 06/03/2004 | US20040106539 Agents for the treatment of viral infections |
| 06/03/2004 | US20040106196 Systems and methods for treating patients with processed lipoaspirate cells |
| 06/03/2004 | US20040106183 Shingolipid ceramide deacylase gene |
| 06/03/2004 | US20040106181 Novel isoform of human camp-dependent protein kinase, calpha -s , localizes to sperm mid-piece and the use thereof |
| 06/03/2004 | US20040106179 Comprises lyases enzymatic peptide for use in screening modulator for treatment and prevention of cardiovascular disorders |
| 06/03/2004 | US20040106174 Designing immunogens |
| 06/03/2004 | US20040106171 Peptides with anti-hypertensive properties |
| 06/03/2004 | US20040106160 Screening assay for antagonists of human leukocyte receptors |
| 06/03/2004 | US20040106148 Polypeptides |
| 06/03/2004 | US20040106143 Monoclonal antibody against estrogen stimulated leucine aminopeptidase |
| 06/03/2004 | US20040106134 Comprises genetically engineered immunoglobulin for use in the treatment of bone disorders |
| 06/03/2004 | US20040106132 Oligonucleotide for generating gene expression profiles in presence of enzyme inhibitors; cancer diagnosis and treatment; antisense therapy |
| 06/03/2004 | US20040106123 Regulation of human g protein-coupled receptor |
| 06/03/2004 | US20040106120 Identifying nucleotide sequence changes/polymorphism associated with abnormal cell adhesion and treating skin, asthma and chronic obstruction pulmonary disease using enzyme inhibitors |
| 06/03/2004 | US20040106116 Methods and materials relating to hematopoietic cytokine-like polypeptides and polynucleotides |
| 06/03/2004 | US20040106107 Extracellular matrix protein for identifying modulators for treatment of cancer, leukemia, solid tumors, nervous system, inflammation, restenotic, diabetic, arthritic and osteoporotic disorders |
| 06/03/2004 | US20040106105 Vaccine |
| 06/03/2004 | US20040105914 Health foods containing natto kinase and fermented milk products |
| 06/03/2004 | US20040105894 Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions |
| 06/03/2004 | US20040105882 a membrane fusion liposome fused to Sendai virus for use in the treatment for arterial disorders or cartilage injuries |
| 06/03/2004 | US20040105874 comprising silicone matrix, a hydrophilic carrier, and at least one active agent comprising proteins, particularly enzymes such as hydrolases and glucose oxidase for enzymatic debridement, clotting formation and clot removal and wound healing |
| 06/03/2004 | US20040105865 Treatment and diagnosis of prostate cancer |
| 06/03/2004 | US20040105861 Use of factor XIIIa inhibitors to treat atherosclerosis |
| 06/03/2004 | US20040105860 Modulation of endothelial cells and cell proliferation and endothelial cells |
| 06/03/2004 | US20040105859 Methods for inhibiting pain |
| 06/03/2004 | US20040105857 Methods and compositions for enhancing angiogenesis |
| 06/03/2004 | US20040105853 controlling genes and metastasis in polynucleotides for infections |
| 06/03/2004 | US20040105852 Parenteral composition for treating bacterial illnesses |
| 06/03/2004 | US20040105851 Treatment of tumors with superoxide dismutase for prevention by applying to tumors |
| 06/03/2004 | US20040105849 spinal muscular atrophy diseases for genetic disorders treatment with vitamin c and pectins, flavonoids, enzyme supplements or enteric bacterium |
| 06/03/2004 | US20040105847 Promoting Recovery from Damage to the Central Nervous System |
| 06/03/2004 | US20040105846 Polynucleotides encoding G protein-coupled receptors |
| 06/03/2004 | US20040105845 Delivering a genetic sequence to cells for gene therapy |
| 06/03/2004 | US20040105844 transfecting herpes simplex virus host cells with ampliicons by genetic engineering packaging a signal and expression vectors |
| 06/03/2004 | US20040105843 prevention of cellular damage in disease resulting from H/I-related blood flow resistance due to occlusion of blood vessels |
| 06/03/2004 | US20040105842 treating an individual having Alzheimer's Disease or at risk for Alzheimer's Disease or other inflammatory/degenerative neurological diseases, comprising the administering an anti-cholinesterase agent and alpha interferon |
| 06/03/2004 | US20040105841 Interferons, uses and compositions related thereto |
| 06/03/2004 | US20040105840 Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| 06/03/2004 | US20040105824 Preventing tooth decay and infective endocarditis using natural oligopeptides |
| 06/03/2004 | DE10361201A1 New biologically active oligopeptides with modified termini, useful as insecticides, acaricides, antibacterials and antitumor agents, especially neoefrapeptins from Geotrichum candidum |
| 06/03/2004 | DE10254439A1 Tubulysine, Herstellungsverfahren und Tubulysin-Mittel Tubulysins, manufacturing methods and means tubulysin |
| 06/03/2004 | DE10252284A1 New cyclic hexapeptides containing a diaminocarboxylic acid residue, useful for, e.g. treating inflammatory or tumor diseases or as diagnostic agents, insecticides or acaricides |
| 06/03/2004 | CA2847795A1 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 06/03/2004 | CA2599222A1 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll) |
| 06/03/2004 | CA2544467A1 Paralytic peptide for use in neuromuscular therapy |
| 06/03/2004 | CA2514089A1 Activation of peptide prodrugs by hk2 |
| 06/03/2004 | CA2507373A1 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 06/03/2004 | CA2506850A1 Compounds and methods for increasing neurogenesis |
| 06/03/2004 | CA2506839A1 Composition and method for treating inflammatory diseases using protease inhibitors |
| 06/03/2004 | CA2506737A1 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll) |
| 06/03/2004 | CA2506684A1 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 |
| 06/03/2004 | CA2506625A1 Autocrine growth factor receptor antibodies and methods |
| 06/03/2004 | CA2506587A1 A process to prepare a pharmaceutically acceptable salt of perindopril |
| 06/03/2004 | CA2506331A1 Protein specific to pancreatic beta cells in islets of langerhans and applications thereof |
| 06/03/2004 | CA2506328A1 Use of hmgb fragments as anti-inflammatory agents |
| 06/03/2004 | CA2506246A1 Products and processes for modulating peptide-peptide binding domain interactions |
| 06/03/2004 | CA2506243A1 Amplified genes involved in cancer |
| 06/03/2004 | CA2506236A1 Compositions and uses of dalbavancin for treatment of bacterial infections |
| 06/03/2004 | CA2506129A1 2'-branched nucleosides and flaviviridae mutation |
| 06/03/2004 | CA2505994A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 06/03/2004 | CA2505922A1 Cytomodulating peptides for treating interstitial cystitis |
| 06/03/2004 | CA2505680A1 Inhibitory oliogonucleotides targeted to bcl-2 |
| 06/03/2004 | CA2505601A1 Complement receptor 2 targeted complement modulators |
| 06/03/2004 | CA2505479A1 Molecular interactions in neurons |
| 06/03/2004 | CA2505377A1 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |